Tenofovir versus entecavir on decreasing risk of HBV-related hepatocellular carcinoma recurrence after liver transplantation

[1] Torre LA(2015)Global cancer statistics, 2012 CA Cancer J Clin 65 87-108

[2] Bray F(2019)Hepatocellular carcinoma recurrence after liver transplantation in a Brazilian multicenter study: clinical profile and prognostic factors of survival Eur J Gastroenterol Hepatol 31 1148-1156

[3] Siegel RL(2019)Long-term observation of hepatocellular carcinoma recurrence after liver transplantation at a European transplantation centre United Eur Gastroenterol J 7 838-849

[4] Ferlay J(2011)Hepatitis B and C virus infection and hepatocellular carcinoma in China: a review of epidemiology and control measures J Epidemiol 21 401-416

[5] Lortet-Tieulent J(2011)High hepatitis B virus DNA level in serum before liver transplantation increases the risk of hepatocellular carcinoma recurrence Digestion 84 134-141

[6] Jemal A(2011)Meta-analysis: the efficacy of anti-viral therapy in prevention of recurrence after curative treatment of chronic hepatitis B-related hepatocellular carcinoma Aliment Pharmacol Ther 33 1104-1112

[7] Chagas AL(2009)Nucleotide analogs for patients with HBV-related hepatocellular carcinoma increase the survival rate through improved liver function Intern Med 48 11-17

[8] Felga GEG(2019)Risk of hepatocellular carcinoma in patients treated with entecavir vs tenofovir for chronic hepatitis B: a Korean nationwide cohort study JAMA Oncol 5 30-36

[9] Diniz MA(2020)Tenofovir is associated with lower risk of hepatocellular carcinoma than entecavir in patients with chronic HBV infection in China Gastroenterology 158 215-225.e6

[10] Silva RF(2021)Tenofovir versus entecavir on recurrence of hepatitis B virus-related hepatocellular carcinoma after surgical resection Hepatology 73 661-673

[1] Torre LA(2015)Global cancer statistics, 2012 CA Cancer J Clin 65 87-108

[2] Bray F(2019)Hepatocellular carcinoma recurrence after liver transplantation in a Brazilian multicenter study: clinical profile and prognostic factors of survival Eur J Gastroenterol Hepatol 31 1148-1156

[3] Siegel RL(2019)Long-term observation of hepatocellular carcinoma recurrence after liver transplantation at a European transplantation centre United Eur Gastroenterol J 7 838-849

[4] Ferlay J(2011)Hepatitis B and C virus infection and hepatocellular carcinoma in China: a review of epidemiology and control measures J Epidemiol 21 401-416

[5] Lortet-Tieulent J(2011)High hepatitis B virus DNA level in serum before liver transplantation increases the risk of hepatocellular carcinoma recurrence Digestion 84 134-141

[6] Jemal A(2011)Meta-analysis: the efficacy of anti-viral therapy in prevention of recurrence after curative treatment of chronic hepatitis B-related hepatocellular carcinoma Aliment Pharmacol Ther 33 1104-1112

[7] Chagas AL(2009)Nucleotide analogs for patients with HBV-related hepatocellular carcinoma increase the survival rate through improved liver function Intern Med 48 11-17

[8] Felga GEG(2019)Risk of hepatocellular carcinoma in patients treated with entecavir vs tenofovir for chronic hepatitis B: a Korean nationwide cohort study JAMA Oncol 5 30-36

[9] Diniz MA(2020)Tenofovir is associated with lower risk of hepatocellular carcinoma than entecavir in patients with chronic HBV infection in China Gastroenterology 158 215-225.e6

[10] Silva RF(2021)Tenofovir versus entecavir on recurrence of hepatitis B virus-related hepatocellular carcinoma after surgical resection Hepatology 73 661-673